peptide backbone comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-11-28. Numbers and descriptions here follow the published literature rather than marketing material.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
retatrutide 是一种人工合成的多肽，设计目标是同时作用于 GIP、GLP-1 与胰高血糖素三种受体。这种三重激动设计试图把多条代谢通路的调节整合进单一分子，而不是只依赖一种肠促胰素受体。分子骨架以天然肽序列为基础，经过非天然氨基酸替换和脂肪酸侧链修饰，以获得更长的作用时间。该方向属于多受体激动剂研究的一部分，与双重激动剂的工作并行推进。
三种受体在能量平衡中的分工并不相同：GLP-1 与 GIP 受体主要参与胰岛素分泌和食欲调节，胰高血糖素受体则与能量消耗及肝糖输出相关。同时激活三者可能产生叠加效应，也可能出现相互制约，具体结果取决于受体亲和力与组织分布。这种组合在理论上可能同时影响体重与血糖指标，但协同关系的细节仍处在研究阶段。
化学修饰延长了分子在体内的停留时间，使较低频次的给药安排成为可能。脂肪酸侧链通过与白蛋白结合延缓清除，非天然氨基酸则降低酶解速率。这些修饰同时改变分子的溶解性与稳定性，需要在制剂设计和储存条件中一并考虑。修饰引入的免疫原性风险也属于开发过程中需要评估的项目。
| Property | Value | Notes |
|---|---|---|
| Molecule class | Synthetic peptide | Engineered triple receptor agonist |
| Molecular weight | Approximately 4731 Da | Reported value; depends on form |
| Receptor targets | GLP-1, GIP, glucagon | Simultaneous activation |
| Development code | LY3437943 | Internal company designation |
| Current status | Investigational | No approved indication reported |
Retatrutide is an investigational peptide studied for obesity and type 2 diabetes. It is a single synthetic molecule designed to activate three metabolic receptors simultaneously. The compound belongs to the incretin mimetic family, a group of peptides that imitate gut hormones involved in appetite and glucose control. Its research code is LY3437943, and it remains under clinical study rather than cleared for routine medical use.
Acting as a triple agonist, the molecule binds the GLP-1, GIP, and glucagon receptors. GLP-1 activity slows gastric emptying and dampens appetite, while GIP signaling contributes to insulin sensitivity and fat metabolism. Glucagon receptor engagement raises energy expenditure and encourages fat breakdown, although it can also elevate blood glucose. Combining three pathways is intended to yield larger weight reduction than single or dual agonists, and researchers continue to examine how the balance among them shapes tolerability.
Identity and purity are established by instrumental methods rather than by appearance. Reversed-phase high-performance liquid chromatography separates the peptide from related impurities and yields a purity value, usually expressed as the share of total peak area. Mass spectrometry checks that the observed mass agrees with the mass calculated from the published sequence, while peptide mapping or amino acid analysis adds structural evidence. Water content, counter-ion identity and residual solvents are sometimes reported as well. A certificate of analysis should name the method behind each figure, because results are method-dependent.
Laboratory handling follows the conventions used for other synthetic peptides. Lyophilized material is weighed and dissolved in an aqueous diluent, typically sterile water or bacteriostatic water, using gentle swirling rather than vigorous shaking, because foaming stresses the chain. Solutions are prepared under clean conditions and, where sterility matters, passed through a suitable filter. Working portions are kept small so that stock material is not repeatedly warmed and cooled, a practice that limits both aggregation and gradual loss of activity.
Aminopeptidase regulator of tumour necrosis factor receptor 1 (TNFR1) shedding (ARTS-1) Adipocyte-derived leucine aminopeptidase (A-LAP) Puromycin-insensitive leucyl-specific aminopeptidase (PILS-AP) KIAA0525 In mice, ER aminopeptidase associated with antigen processing (ERAAP)
These positions were eventually quashed by two important advancements that happened later in the 19th century: the development of the periodic table and the discovery that molecules have an internal architecture that determines their properties.
==== Bill Clinton ==== Hitchens became increasingly disenchanted by the presidency of Bill Clinton, accusing him of being a rapist, a liar, and war criminal. Hitchens said the missile attacks by Clinton on Sudan constituted a war crime. Hitchens criticized Clinton for his pardon of Marc Rich and others who had donated to Clinton, overseeing the execution of Ricky Ray Rector, his relationships with Monica Lewinsky and Gennifer Flowers. In 1999, Hitchens became involved in the Impeachment trial of Bill Clinton when Hitchens friend and Clinton adviser Sidney Blumenthal said under oath during a deposition that he had never described Monica Lewinsky as a stalker. In response to Blumenthal's testimony Hitchens submitted a sworn affidavit saying that he had in fact described Lewinsky as a stalker at a lunch with Hitchens and his wife.
A poultice or cataplasm, also called a fomentation, is a soft moist mass, often heated and medicated, that is applied to the skin to reduce inflammation, soothe pain, promote healing, or otherwise treat wounds or ailments. Soft materials like cereals serve as a base for agents intended to affect the body transdermally. The preparation is usually spread on cloth, which is then applied to the area being treated. The cloth is used to keep the preparation in place, or additional bandaging to hold the poultice may be employed. Direct topical application (without cloths) is also used. The term "poultice" may also refer to a porous solid, filled with a solvent, and used to remove stains from porous stone such as marble or granite.
The Nobel Prize in Physiology or Medicine (Swedish: Nobelpriset i fysiologi eller medicin) is awarded annually by the Swedish Karolinska Institute to scientists in the various fields of physiology or medicine. It is one of the five Nobel Prizes established by the 1895 will of Alfred Nobel (who died in 1896), awarded for outstanding contributions in chemistry, physics, literature, peace, and physiology or medicine. As dictated by Nobel's will, the award is administered by the Nobel Foundation and awarded by a committee that consists of five members and an executive secretary elected by the Karolinska Institute. While commonly referred to as the Nobel Prize in Medicine, Nobel specifically stated that the prize be awarded for "physiology or medicine" in his will. Because of this, the prize can be awarded in a broader range of fields. The first Nobel Prize in Physiology or Medicine was awarded in 1901 to Emil Adolf von Behring, of Germany. Each recipient receives a medal, a diploma and a monetary award that has varied throughout the years. In 1901, von Behring received 150,782 SEK, which was equal to 7,731,004 SEK in December 2008. The award is presented in Stockholm at an annual ceremony on 10 December, the anniversary of Nobel's death. Laureates have won the Nobel Prize in a wide range of fields that relate to physiology or medicine.
Sources: en.wikipedia.org
== Outcomes == The primary measures of weight loss outcomes for endoscopic bariatric therapies include total body weight loss (percentage of pre-procedure weight lost by a certain time point) and excess weight loss (percentage of pre-procedure weight above ideal body weight that is lost by a certain time point). The Preservation and Incorporation of Valuable Endoscopic Innovation thresholds is an expert panel with gastroenterologists and surgeons from the American Society for Gastrointestinal Endoscopy and The American Society for Metabolic and Bariatric Surgery, and in 2015, this panel recommended that any new endoscopic therapy for weight loss should have an excess weight loss exceeding 25% and a serious adverse event rate less than 5%. Total body weight loss thresholds were not defined but are generally considered meaningful in novel endoscopic bariatric therapies if exceeding 5%. Multiple studies of ESG have shown that this therapy satisfies these criteria, as outlined below.
==== Chiral mobile phase additive (CMPA) ==== In this approach, an enantiomerically pure compound, the chiral selector, is added to the mobile phase and separation happens on a conventional achiral column. When a mixture of enantiomers is introduced into the chromatographic system, the individual enantiomers form transient diastereomeric complexes with the chiral mobile phase additive. In the chiral mobile phase additive technique, two possible mechanisms may operate: one possibility is that CMPA and the enantiomers may form diastereomers in the mobile phase. Another is that the stationary phase may be coated with the CMPA, leading to diastereomeric interactions with the enantiomeric pairs during chromatographic separation process. It is observed that both the mechanisms may happen depending on the characteristic of the stationary phase and mobile phase employed. Of late this method finds limited application.
Since the commissioning of the first commercial nuclear power plants (USA 1956, Germany 1962), various final storage concepts for radioactive materials have been proposed in the following decades, of which only storage in deep geological formations appeared to be safe and feasible within a reasonable period of time and was pursued further. Due to the high activity of the short-lived fission products, spent fuel is initially handled only under water and stored for several years in a decay pool. The water is used for cooling and also shields much of the emitted radiation. This is followed either by reprocessing or by decades of interim storage. Waste from reprocessing must also be stored temporarily until the heat has decreased enough to allow final disposal. Casks are special containers for the storage and transport of highly radioactive materials. Their maximum permissible dose rate is 0.35 mSv/h, of which a maximum of 0.25 mSv/h is due to neutron radiation. The safety of these transport containers has been discussed every three years since 1980 at the International Symposium on the Packaging and Transportation of Radioactive Materials (PATRAM). Following various experiments, such as the Gorleben exploratory mine or the Asse mine, a working group on the selection procedure for repository sites (AkEnd) developed recommendations for a new selection procedure for repository sites between 1999 and 2002. In Germany, the Site Selection Act was passed in 2013 and the Act on the Further Development of the Site Search was passed on March 23, 2017.
==== Epigenetic modifications ==== Differences in gene activation between maternal and fetal DNA can be exploited. Epigenetic modifications (heritable modifications that change gene function without changing DNA sequence) can be used to detect cffDNA. The hypermethylated RASSF1A promoter is a universal fetal marker used to confirm the presence of cffDNA. A technique was described where cffDNA was extracted from maternal plasma and then digested with methylation-sensitive and insensitive restriction enzymes. Then, real-time PCR analysis of RASSF1A, SRY, and DYS14 was done. The procedure detected 79 out of 90 (88 percent) maternal blood samples where hypermethylated RASSF1A was present.
Sources: en.wikipedia.org
=== October === 1 October – Prime Minister Rishi Sunak announces £20m of levelling up funding to help regenerate seven Scottish towns that are described as having been overlooked. 2 October – ScotRail begins a six months trial during which peak time train fares are scrapped. 3 October – Aberdeen City Council says that reinforced autoclaved aerated concrete (RAAC) is likely to have been used in hundreds of properties in the city. 4 October – Police Scotland pays £60,000 compensation to four traffic officers told to shave off their beards before the force implemented its delayed proposals for a clean shaven policy. 5 October – Labour's Michael Shanks wins the Rutherglen and Hamilton West by-election. 6 October – Police Scotland scraps plans to recruit an extra 200 officers in January 2024 as it attempts to save costs following a projected overspend of £19m. 7 October – The Met Office issues an amber weather alert for heavy rain in Scotland, while roads and train services are disrupted by flooding. Ten people are airlifted to safety after heavy rain causes landslides on two roads in Argyll. 9 October – Bernard Cowan, a grandfather who grew up in the Glasgow area, is confirmed as one of the people killed during a series of attacks launched by Hamas against Israel on 7 October. Humza Yousaf, the First Minister of Scotland, condemns the attacks and expresses concern for his in-laws, who are "trapped" in Gaza after travelling there to visit relatives. The Scottish Medicines Consortium (SMC) approves the weight loss drug semaglutide for use by NHS Scotland.
This micelle controlled technique provides for unique opportunities for solving complicated separation problems. Despite the poor efficiency of MLC, it has been successfully used in many applications. The use of MLC in the future appears to be extremely advantages in the areas of physiological fluids, pharmaceuticals, and even inorganic ions. The technique has proven to be superior over ion-pairing and ion-exchange for many applications. As new approaches are developed to combat the poor efficiency of MLC, its application is sure to spread and gain more acceptance.
== Function == Within blood, thrombins cleave fibrinogens to fibrins during coagulation and a fibrin-based blood clot forms. Factor XIII is a transglutaminase that circulates in human blood as a heterotetramer of two A and two B subunits. Factor XIII binds to the clot via their B units. In the presence of fibrins, thrombin efficiently cleaves the R37–G38 peptide bond of each A unit within a XIII tetramer. A units release their N-terminal activation peptides. Both of the non-covalently bound B units are now able to dissociate from the tetramer with the help of calcium ions (Ca2+) in the blood; these ions also activate the remaining dimer of two A units via a conformational change. Factor XIIIa (dimer of two active A units) crosslinks fibrins within the clot by forming isopeptide bonds between various glutamines and lysines of the fibrins. These bonds make the clot physically more durable and protect it from premature enzymatic degradation (fibrinolysis). In humans, plasmin, antithrombin and TFPI are the most relevant proteolytic inhibitors of the active factor XIIIa. α2-macroglobulin is a significant non-proteolytic inhibitor.
== See also == Trimethoxyamphetamine Substituted methoxyphenethylamine 2,4,5-Trimethoxyphenethylamine (2,4,5-TMPEA; 2C-O) 2,5-Dimethoxyamphetamine (2,5-DMA; DMA-4; DOH) 2,4-Dimethoxyamphetamine (2,4-DMA; DMA-3)
== Medical uses == EDE, a long-acting estrogen, was used in combination with EB, a short-acting estrogen, and TEBH, a long-acting androgen/anabolic steroid, in menopausal hormone therapy in perimenopausal, postmenopausal, hypogonadal, and oophorectomized women, as well as for suppression of lactation in postpartum women.
Sources: en.wikipedia.org
Retatrutide is an investigational peptide that activates the GLP-1, GIP, and glucagon receptors at the same time. It is being studied for obesity and type 2 diabetes and has not been approved for clinical use. The internal code LY3437943 refers to the same molecule.
Most approved incretin therapies target one or two receptors, while retatrutide engages three. The addition of glucagon receptor activity is intended to raise energy expenditure. This broader mechanism is the subject of ongoing research rather than established practice.
No regulatory agency has approved retatrutide for any indication as of available public information. Development remains in later-stage trials. Availability claims found online should be treated as unverified.
指同一个分子能激活 GIP、GLP-1 和胰高血糖素三类受体。它与只激活一到两种受体的同类分子在设计思路上有所区别。这种设计的目的在于覆盖更多代谢调节通路。